Eli Lilly obesity drug Zepbound led to 47% greater relative weight loss compared to Wegovy in a head-to-head clinical trial. The results could help Lilly differentiate its product from Novo Nordisk’s in the increasingly competitive market of obesity medications.
The post Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test appeared first on MedCity News.
